Novo-researcher turned PhD project into company and prepares for phase II
Sweden-based biotech firm Pila Pharma is about to initiate a phase II study with a brand new form of type 2 diabetes treatment. What started as a PhD project in Novo Nordisk's laboratories is now to be transformed into a cost-effective therapy that can compete with other classes of diabetes drugs.
At the turn of the millennium, Dorte Gram often visited Novo Nordisk as a PhD student from university of Copenhagen, and until 2009 she worked as a researcher for the Danish drug group.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Novo's innovation hunter brings back abandoned project
For abonnenter
.jpg&w=384&q=75){kind=logo}
